LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,416,493
تعداد دریافت فایل اصل مقاله11,292,624
Heidari, Maryam, Amouheidari, Alireza, Hemati, Simin, Khanahmad, Hossein, Rahimmanesh, Ilnaz, Jafari, Peyman, Shokrani, Parvaneh. (1403). Prospective Prediction of Treatment Response in High-Grade Glioma Patients using Pre-Treatment Tumor ADC Value and miR-222 and miR-205 Expression Levels in Plasma. سامانه مدیریت نشریات علمی, 14(2), 111-118. doi: 10.31661/jbpe.v0i0.2108-1376
Maryam Heidari; Alireza Amouheidari; Simin Hemati; Hossein Khanahmad; Ilnaz Rahimmanesh; Peyman Jafari; Parvaneh Shokrani. "Prospective Prediction of Treatment Response in High-Grade Glioma Patients using Pre-Treatment Tumor ADC Value and miR-222 and miR-205 Expression Levels in Plasma". سامانه مدیریت نشریات علمی, 14, 2, 1403, 111-118. doi: 10.31661/jbpe.v0i0.2108-1376
Heidari, Maryam, Amouheidari, Alireza, Hemati, Simin, Khanahmad, Hossein, Rahimmanesh, Ilnaz, Jafari, Peyman, Shokrani, Parvaneh. (1403). 'Prospective Prediction of Treatment Response in High-Grade Glioma Patients using Pre-Treatment Tumor ADC Value and miR-222 and miR-205 Expression Levels in Plasma', سامانه مدیریت نشریات علمی, 14(2), pp. 111-118. doi: 10.31661/jbpe.v0i0.2108-1376
Heidari, Maryam, Amouheidari, Alireza, Hemati, Simin, Khanahmad, Hossein, Rahimmanesh, Ilnaz, Jafari, Peyman, Shokrani, Parvaneh. Prospective Prediction of Treatment Response in High-Grade Glioma Patients using Pre-Treatment Tumor ADC Value and miR-222 and miR-205 Expression Levels in Plasma. سامانه مدیریت نشریات علمی, 1403; 14(2): 111-118. doi: 10.31661/jbpe.v0i0.2108-1376

Prospective Prediction of Treatment Response in High-Grade Glioma Patients using Pre-Treatment Tumor ADC Value and miR-222 and miR-205 Expression Levels in Plasma

Journal of Biomedical Physics and Engineering
دوره 14، شماره 2، تیر 2024، صفحه 111-118    اصل مقاله (865.08 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2108-1376
نویسندگان
Maryam Heidari1؛ Alireza Amouheidari2؛ Simin Hemati3؛ Hossein Khanahmad4؛ Ilnaz Rahimmanesh5؛ Peyman Jafari6؛ Parvaneh Shokrani* 1
1Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2Department of Radiation Oncology, Isfahan Milad Hospital, Isfahan, Iran
3Department of Radiotherapy Oncology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
5Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
6Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: Treatment response in High-grade Glioma (HGG) patients changes based on their genetic and biological characteristics. MiRNAs, as important regulators of drug and radiation resistance, and the Apparent Diffusion Coefficients (ADC) value of tumor can be used as a prognostic predictor for glioma.
Objective: This study aimed to identify some of the pre-treatment individual patient features for predicting the treatment response in HGG patients.
Material and Methods: In this prospective study, 18 HGG patients, who were candidated for chemo-radiation treatment, participated after informed consent of the patients. The investigated features were the expression level of miR-222 and miR-205 in plasma, the ADC value of tumor, Body Mass Index (BMI), and age. Treatment response was assessed, and Least Absolute Shrinkage and Selection Operator (LASSO) regression was used to obtain a model to predict the treatment response. Mann-Whitney U test was also applied to select the variables with a significant relationship with patients’ treatment response.
Results: The LASSO coefficients for miR-205, miR-222, tumor’s mean ADC value, BMI, and age were 3.611, -1.683, 2.468, -0.184, and -0.024, respectively. Mann-Whitney U test results showed miR-205 and tumor’s mean ADC significantly related to treatment response (P-value˂0.05). 
Conclusion: The miR-205 expression level of the patient in plasma and tumor’s mean ADC value has the potential for prognostic predictors in HGG.

تازه های تحقیق

Maryam Heidari  (Google Scholar)

Parvaneh Shokrani  (Google Scholar)

کلیدواژه‌ها
MicroRNAs؛ ADC Map؛ Regression Analysis؛ LASSO Model؛ Glioma
سایر فایل های مرتبط با مقاله
مراجع
  1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9):494-503. doi: 10.1038/ncpneuro0289. PubMed PMID: 16932614.
  2. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255-68. doi: 10.1111/j.1750-3639.1993.tb00752.x. PubMed PMID: 8293185.
  3. Fathi Kazerooni A, Bakas S, Saligheh Rad H, Davatzikos C. Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review. J Magn Reson Imaging. 2020;52(1):54-69. doi: 10.1002/jmri.26907. PubMed PMID: 31456318. PubMed PMCID: PMC7457548.
  4. Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, et al. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016;5(8):1917-46. doi: 10.1002/cam4.775. PubMed PMID: 27282910. PubMed PMCID: PMC4971921.
  5. Huse JT, Phillips HS, Brennan CW. Molecular subclassification of diffuse gliomas: seeing order in the chaos. 2011;59(8):1190-9. doi: 10.1002/glia.21165. PubMed PMID: 21446051.
  6. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010;120(5):567-84. doi: 10.1007/s00401-010-0736-4. PubMed PMID: 20714900. PubMed PMCID: PMC2955236.
  7. Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediate­d gene silencing. Nat Rev Genet. 2015;16(7):421-33. doi: 10.1038/nrg3965. PubMed PMID: 26077373.
  8. Santangelo A, Tamanini A, Cabrini G, Dechecchi MC. Circulating microRNAs as emerging non-invasive biomarkers for gliomas. Ann Transl Med. 2017;5(13):277. doi: 10.21037/atm.2017.06.15. PubMed PMID: 28758103. PubMed PMCID: PMC5515812.
  9. Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016;124(1):122-8. doi: 10.3171/2015.1.JNS141577. PubMed PMID: 26230475.
  10. Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q, Tao R. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep. 2012;27(4):1200-6. doi: 10.3892/or.2011.1588. PubMed PMID: 22159356. PubMed PMCID: PMC3583473.
  11. Xiao Y, Zhang L, Song Z, Guo C, Zhu J, Li Z, Zhu S. Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma. Med Sci Monit. 2016;22:855-62. doi: 10.12659/msm.897164. PubMed PMID: 26978735. PubMed PMCID: PMC4795091.
  12. Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017;16(1):59. doi: 10.1186/s12943-017-0628-5. PubMed PMID: 28284220. PubMed PMCID: PMC5346242.
  13. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672-5. doi: 10.1111/j.1365-2141.2008.07077.x. PubMed PMID: 18318758.
  14. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, et al. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2010;296(2):241-8. doi: 10.1016/j.canlet.2010.04.013. PubMed PMID: 20444541.
  15. Durand-Muñoz C, Flores-Alvarez E, Moreno-Jimenez S, Roldan-Valadez E. Pre-operative apparent diffusion coefficient values and tumour region volumes as prognostic biomarkers in glioblastoma: correlation and progression-free survival analyses. Insights Imaging. 2019;10(1):36. doi: 10.1186/s13244-019-0724-8. PubMed PMID: 30887267. PubMed PMCID: PMC6423260.
  16. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9(1):53-60. doi: 10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2. PubMed PMID: 10030650.
  17. Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, et al. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol. 2016;37(7):8993-9000. doi: 10.1007/s13277-015-4513-9. PubMed PMID: 26758430.
  18. Zhao F, Li M, Kong L, Zhang G, Yu J. Delineation of radiation therapy target volumes for patients with postoperative glioblastoma: a review. Onco Targets Ther. 2016;9:3197-204. doi: 10.2147/OTT.S104241. PubMed PMID: 27313465. PubMed PMCID: PMC4892826.
  19. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. PubMed PMID: 20231676.
  20. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010;33(1):1-22. PubMed PMID: 20808728. PubMed PMCID: PMC2929880.
  21. Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013;132(1):116-27. doi: 10.1002/ijc.27657. PubMed PMID: 22674182.
  22. Chen W, Kong KK, Xu XK, Chen C, Li H, Wang FY, et al. Downregulation of miR 205 is associated with glioblastoma cell migration, invasion, and the epithelial-mesenchymal transition, by targeting ZEB1 via the Akt/mTOR signaling pathway. Int J Oncol. 2018;52(2):485-95. doi: 10.3892/ijo.2017.4217. PubMed PMID: 29345288.
  23. Li FF, Xing C, Wu LL, Xue F. MiR-205 enhances cisplatin sensitivity of glioma cells by targeting E2F1. Eur Rev Med Pharmacol Sci. 2018;22(2):299-306. doi: 10.26355/eurrev_201801_14172. PubMed PMID: 29424887.
  24. Li W, Guo F, Wang P, Hong S, Zhang C. miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Curr Mol Med. 2014;14(1):185-95. doi: 10.2174/1566524013666131203103147. PubMed PMID: 24295494.
  25. Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119. doi: 10.1186/1479-5876-10-119. PubMed PMID: 22681957. PubMed PMCID: PMC3403924.
  26. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, Jia ZF, et al. MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 2010;9:229. doi: 10.1186/1476-4598-9-229. PubMed PMID: 20813046. PubMed PMCID: PMC2939570.
  27. Chen L, Zhang J, Han L, Zhang A, Zhang C, Zheng Y, et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep. 2012;27(3):854-60. doi: 10.3892/or.2011.1535. PubMed PMID: 22075712.
آمار
تعداد مشاهده مقاله: 158,509
تعداد دریافت فایل اصل مقاله: 449


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب